Ipamorelin vs CJC-1295 vs Sermorelin: What's Actually Different

They Are Not Variations on a Theme

The most common framing of this comparison — three similar compounds, pick one — is wrong at the first step. These compounds act on two entirely different receptors, and the distinction is the key to understanding everything else about them.

Sermorelin and CJC-1295 are the same *kind* of molecule. Ipamorelin is a different kind entirely. Grouping them as three interchangeable options obscures the one fact that actually explains their behaviour.

The Two Receptor Systems

Growth hormone release from the pituitary is governed by an opposed system:

GHRH (growth hormone-releasing hormone) is the accelerator. Released from the hypothalamus, it acts on GHRH receptors on pituitary somatotrophs, stimulating both GH synthesis and release.

Somatostatin is the brake, inhibiting GH release.

Ghrelin acts on a third, separate receptor — the growth hormone secretagogue receptor (GHS-R1a) — and does two things: it directly stimulates GH release, *and* it suppresses somatostatin.

So there are two independent ways to increase GH output: push the accelerator (GHRH pathway), or work the ghrelin pathway, which both pushes and releases the brake.

That is the entire pharmacological logic of this compound class, and it explains why the two types are combined.

The GHRH Analogues

Sermorelin

Sermorelin is GHRH(1-29) — the first 29 amino acids of endogenous GHRH, which is the shortest fragment retaining full biological activity. It is, essentially, the natural hormone truncated to its active core.

It has a genuine clinical history. Sermorelin was an approved drug (marketed as Geref) used in the diagnosis and treatment of growth hormone deficiency, and was subsequently discontinued — a commercial decision rather than a safety withdrawal.

Its defining pharmacological property is a very short half-life, on the order of 10–20 minutes. It produces a sharp, brief GH pulse that closely resembles physiological release.

CJC-1295 — and the distinction almost everyone gets wrong

"CJC-1295" refers to two pharmacologically different molecules, and vendors routinely fail to specify which one they are selling.

CJC-1295 with DAC. DAC stands for Drug Affinity Complex — a maleimide linker that covalently binds to serum albumin after administration. Albumin is a long-lived plasma protein, so tethering the peptide to it extends the half-life dramatically, into the range of several days. This produces a sustained elevation in GH and IGF-1 — a "bleed" rather than a pulse.

CJC-1295 without DAC. This is Modified GRF(1-29) — often sold as "Mod GRF 1-29." It carries amino acid substitutions that resist DPP-4 degradation, giving it a half-life around 30 minutes. Longer than sermorelin, but still a pulse-generating compound, not a sustained one.

The difference between these two is not a detail. It is the difference between a compound with a half-life measured in minutes and one measured in days, with correspondingly different effects on the GH release profile.

If a vendor lists "CJC-1295" without stating DAC or no-DAC, they either do not know what they are selling or are not telling you. Ask. If they cannot answer, that is your answer.

The Ghrelin Mimetic

Ipamorelin

Ipamorelin is a selective GHS-R1a agonist — a synthetic ghrelin mimetic. It belongs to the GHRP family alongside GHRP-2, GHRP-6 and hexarelin.

Its defining characteristic is selectivity, and this is the reason it is the most-discussed member of the family.

The earlier GHRPs are pharmacologically messy. GHRP-6 produces pronounced hunger (a direct consequence of agonism at the ghrelin receptor, ghrelin being the hunger hormone). GHRP-2 and hexarelin meaningfully elevate cortisol and prolactin alongside GH.

Ipamorelin, in the published pharmacology, stimulates GH release with minimal effect on cortisol, prolactin and ACTH. It is the clean member of a dirty family, and that selectivity — not potency — is its entire selling point. Hexarelin is a *more* potent GH releaser; it is simply less selective.

Why the Two Types Get Combined

This is the pharmacological rationale behind blended vials such as CJC-1295 + Ipamorelin, and it is legitimate pharmacology rather than marketing.

The two compounds act at different receptors, and their effects are more than additive:

1. The GHRH analogue drives GH synthesis and release through the GHRH receptor.

2. The ghrelin mimetic drives release through GHS-R1a and suppresses somatostatin — lifting the brake.

Pushing the accelerator while releasing the brake produces a greater GH response than either alone. That is the mechanism, and it is well described in the pharmacology literature.

What the mechanism does not tell you is whether any of this produces an outcome a person would care about. See below.

If you are working with a blended vial, note the practical constraint covered in our concentration maths guide: the ratio of the two components is fixed at manufacture and cannot be varied. Every draw contains both, locked together.

Summary Table

The Honest Limitation

Everything above is pharmacology — receptor binding, half-life, hormone release. On that ground the evidence is real: these compounds do raise GH and IGF-1, and this is measurable in humans.

But elevating a biomarker is not the same as producing an outcome. The question people actually care about — whether raising GH via a secretagogue produces meaningful changes in body composition, recovery, sleep or ageing — is not answered by the fact that GH goes up. It would be answered by controlled trials with those endpoints, and for these compounds those trials have not been done.

Sermorelin's clinical history is the exception, and it is narrow: it was used in the context of diagnosed growth hormone deficiency, which is a specific pathological state and not the population discussing these compounds online.

So the honest position is: the mechanism is well understood, the biomarker response is real, and the outcome evidence does not exist. Anyone telling you otherwise is extrapolating past the data.

Disclaimer: All information is drawn from published pharmacological and preclinical literature and is provided for educational purposes only. This article does not provide dosing or administration guidance. All products are supplied strictly for in-vitro laboratory and research use, not for human consumption. Not medical advice.